Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
NCT00315380
Recruiting
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/15/2025
Locations: University of California San Diego, San Diego, California +9 locations
Conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Register for Updates
The Pediatric Anesthesia Quality Improvement Project
NCT00674388
Recruiting
The Study is designed to collect information about adverse events that occur in children undergoing anesthesia in participating hospitals. Demographic information will be collected on all anesthetics. An analysis of each adverse event will be performed and entered into the database. From this information we will devise strategies to prevent these adverse events.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/15/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona +36 locations
Conditions: Surgery, Anesthesia, Children
Register for Updates
Hereditary Risk Factors for Thyroid Cancer
NCT02747888
Recruiting
Thyroid cancers can occur sporadically, but can also be found as tumors that cluster in families with other cancers or genetic syndromes. Researchers are studying thyroid cancer in children and families, with a particular interest in understanding genes and other factors that may put individuals at risk for developing thyroid cancer and thyroid nodules. * In this study, family and medical history information is collected alongside a blood or saliva sample for genetic studies. * Individuals with... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/15/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Thyroid Cancer
Register for Updates
Fludarabine Based RIC for Bone Marrow Failure Syndromes
NCT02928991
Recruiting
This is a pilot study to determine whether fludarabine-based reduced intensity conditioning (RIC) regimens facilitate successful donor engraftment of patients with acquired aplastic anemia (AA) and Inherited bone marrow failure (iBMF) syndromes undergoing Matched related donor bone marrow transplant (MRD-BMT).
Gender:
ALL
Ages:
22 years and below
Trial Updated:
05/15/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Bone Marrow Failure Syndromes
Register for Updates
Tranexamic Acid in Adult Spinal Deformity Surgery
NCT03553186
Recruiting
Posterior spinal surgery for adult deformity is associated with high incidence of blood loss and need for blood transfusion and intraoperative blood salvage, with associated increased cost and risk for perioperative complications. Tranexamic acid (TXA) is relatively inexpensive anti-fibrinolytic agent that has been proven effective for decreasing intraoperative blood loss in various surgical specialties. Intravenous TXA (ivTXA) is routinely used at our institution for adult spinal deformity case... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/15/2025
Locations: Hospital for Special Surgery, New York, New York
Conditions: Spinal Deformity, Degenerative Lumbar Spinal Stenosis, Blood Loss, Surgical
Register for Updates
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
NCT03914794
Recruiting
This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC tumors. Participants will receive pemigatinib for 4-6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Sibley Memorial Hospital, Washington, District of Columbia +5 locations
Conditions: Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent
Register for Updates
Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.
NCT03958565
Recruiting
The purpose of this study is to assess percentage reduction in the of urine NTX and serum CTX , in patients with NSCLC and bone metastases 1) with actionable driver oncogene on standard of care (SOC) TKI at 3 months post treatment and 2) without actionable mutations on standard of care therapy (chemotherapy/immunotherapy) treated with zoledronic acid or denosumab at the same time period.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/15/2025
Locations: University of Colorado Hospital, Aurora, Colorado +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy
NCT03958747
Recruiting
This pilot clinical trial studies how well ultrasound works in detecting oxaliplatin-induced neuropathy in patients with gastrointestinal cancer. Ultrasound may work better in diagnosing and detecting neuropathy in gastrointestinal cancer patients treated with the chemotherapy drug called a oxaliplatin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Gastrointestinal Cancer, Colorectal Cancer
Register for Updates
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
NCT03997370
Recruiting
This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona +178 locations
Conditions: Malignant Solid Neoplasm
Register for Updates
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
NCT04060017
Recruiting
The primary objective of this study is to evaluate the cognitive and behavioral effects of liquid leucovorin calcium on young children with autism spectrum disorder (ASD) and determine whether it improves language as well as the core and associated symptoms of ASD. The investigators will enroll 80 children across two sites, between the ages of 2.5 and 5 years, with confirmed ASD and known language delays or impairments. Participation will last approximately 26 weeks from screening to end of trea... Read More
Gender:
ALL
Ages:
Between 30 months and 60 months
Trial Updated:
05/15/2025
Locations: Southwestern Autism Research & Resource Center, Phoenix, Arizona +1 locations
Conditions: Autism Spectrum Disorder, Language Disorders
Register for Updates
Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism
NCT04060030
Recruiting
The primary objective of this study is to evaluate the cognitive and behavioral effects of liquid leucovorin calcium on young children with autism spectrum disorder (ASD) and determine whether it improves social communication as well as the core and associated symptoms of ASD. The investigators will enroll 80 children across two sites, between the ages of 2.5 and 5 years, with confirmed ASD and known social and communication delays. Participation will last approximately 26 weeks, from screening... Read More
Gender:
ALL
Ages:
Between 30 months and 60 months
Trial Updated:
05/15/2025
Locations: Southwestern Research & Resource Center, Phoenix, Arizona +1 locations
Conditions: Autism Spectrum Disorder, Language Disorders
Register for Updates
LITES Task Order 0005 Prehospital Airway Control Trial (PACT)
NCT04100564
Recruiting
The Prehospital Airway Control Trial (PACT) is a proposed 5 year, open label, multi-center, stepped-wedge randomized trial comparing airway management strategies of prehospital trauma patients. The initial airway attempt will be randomized to either usual care (control) or a supraglottic airway management approach (intervention). The primary outcome will be 24 hour survival, with secondary outcomes to include survival to hospital discharge, expected clinical adverse events, airway management per... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
05/15/2025
Locations: Emory University, Atlanta, Georgia +13 locations
Conditions: Trauma Injury, Airway Control
Register for Updates